6892 Stock Overview
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Taiwan Bio Therapeutics Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$37.10 |
| 52 Week High | NT$40.30 |
| 52 Week Low | NT$31.10 |
| Beta | 0 |
| 1 Month Change | 4.65% |
| 3 Month Change | 9.12% |
| 1 Year Change | -5.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6892 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.5% | 3.2% | 1.1% |
| 1Y | -5.5% | -24.1% | 28.2% |
Return vs Industry: 6892 exceeded the TW Biotechs industry which returned -24.1% over the past year.
Return vs Market: 6892 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
| 6892 volatility | |
|---|---|
| 6892 Average Weekly Movement | 2.9% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6892 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6892's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.twbio-thera.com |
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Taiwan Bio Therapeutics Co., Ltd Fundamentals Summary
| 6892 fundamental statistics | |
|---|---|
| Market cap | NT$1.89b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6892 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6892 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6892 perform over the long term?
See historical performance and comparison